Hematological manifestations and complications of Gaucher disease

References

• Revel-Vilk S, Szer J, Zimran A. Gaucher disease and related lysosomal storage diseases. In: Kaushansky K, Lichtman M, Prchal J. et al., editors. Williams Hematology. 10th. McGraw-Hill: New York; 2021:1189-1202.
   Google Scholar
• Schiffmann R, Sevigny J, Rolfs A, et al. The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 2020 Sep;43(5):1056–1059.
   PubMed Web of Science ®Google Scholar
• Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991 May 23;324(21):1464–1470.
   PubMed Web of Science ®Google Scholar
• Gary SE, Ryan E, Steward AM, et al. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 2018 Mar;13(2):107–118.
   PubMed Web of Science ®Google Scholar
• Revel-Vilk S, Fuller M, Zimran A. Value of glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher Disease: a systematic literature review. Int J Mol Sci. 2020Sep28;21(19):7159.
   Web of Science ®Google Scholar
• Mehta A, Belmatoug N, Bembi B, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017 Aug 04;122(3):122–129.
   PubMed Web of Science ®Google Scholar
• Gielchinsky Y, Elstein D, Hadas-Halpern I, et al. Is there a correlation between degree of splenomegaly, symptoms and hypersplenism? A study of 218 patients with Gaucher disease. Br J Haematol. 1999 Sep;106(3):812–816.
   PubMed Web of Science ®Google Scholar
• Grover SA, Barkun AN, Sackett DL. Does this patient have splenomegaly? JAMA. 1993;270(18):2218–2221.
   PubMed Web of Science ®Google Scholar
• Neudorfer O, Hadas-Halpern I, Elstein D, et al. Abdominal ultrasound findings mimicking hematological malignancies in a study of 218 Gaucher patients. Am J Hematol. 1997 May;55(1):28–34.
   PubMed Web of Science ®Google Scholar
• Andrade-Campos MM, De Frutos LL, Cebolla JJ, et al. Identification of risk features for complication in Gaucher’s disease patients: a machine learning analysis of the Spanish registry of Gaucher disease. Orphanet J Rare Dis. 2020 Sep 22;15(1):256.
   PubMed Web of Science ®Google Scholar
• Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab. 2002 Sep-Oct;77(1–2):91–98.
   PubMed Web of Science ®Google Scholar
• Freund MR, Reissman P, Zimran A, et al. Splenectomy in Gaucher Disease: a call for minimally invasive surgery. Surg Laparosc Endosc Percutan Tech. 2018;28(2):86–89.
   PubMed Web of Science ®Google Scholar
• Aharoni D, Hadas-Halpern I, Elstein D, et al. Huge subcapsular splenic hematoma in a patient with Gaucher disease. Isr Med Assoc J. 2000 Jan;2(1):61–62.
   PubMed Web of Science ®Google Scholar
• Hughes D, Mikosch P, Belmatoug N, et al. Gaucher disease in bone: from pathophysiology to practice. J Bone Miner Res. 2019 Jun;34(6):996–1013.
   PubMed Web of Science ®Google Scholar
• Rosenbaum H. Hemorrhagic aspects of Gaucher disease. Rambam Maimonides Med J. 2014 Oct;5(4):e0039.
   PubMedGoogle Scholar
• Rosenbaum H, Napso T, Bonstein L. Immune thrombocytopenia in Type I Gaucher Disease. Blood. 2007;110(11):3200.
   Web of Science ®Google Scholar
• Stein P, Malhotra A, Haims A, et al. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. J Inherit Metab Dis. 2010 Dec;33(6):769–774.
   PubMed Web of Science ®Google Scholar
• Beutler E, Saven A. Misuse of marrow examination in the diagnosis of Gaucher disease. Blood. 1990;76(3):646–648.
   PubMed Web of Science ®Google Scholar
• Zimran A, Elstein D, Gonzalez DE, et al. Treatment-naive Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials. Blood Cells Mol Dis. 2018;68:153–159.
   Web of Science ®Google Scholar
• Stein P, Yu H, Jain D, et al. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol. 2010 Jul;85(7):472–476.
   PubMed Web of Science ®Google Scholar
• Mehta A, Kuter DJ, Salek SS, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher earlier diagnosis consensus (GED-C) Delphi initiative. Intern Med J. 2019 May;49(5):578–591.
   PubMed Web of Science ®Google Scholar
• Gielchinsky Y, Elstein D, Green R, et al. High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population. Br J Haematol. 2001 Dec;115(3):707–709.
   PubMed Web of Science ®Google Scholar
• Basgalupp SP, Siebert M, Ferreira C, et al. Assessment of cellular cobalamin metabolism in Gaucher disease.. BMC Med Genet. 2020;21(1):12.
   PubMed Web of Science ®Google Scholar
• Zimran A, Altarescu G, Rudensky B, et al. Survey of hematological aspects of Gaucher disease. Hematology. 2005;10(2):151–156.
   PubMed Web of Science ®Google Scholar
• Serratrice C, Cherin P, Lidove O, et al. Coagulation parameters in adult patients with type-1 Gaucher disease. J Hematol. 2019 Sep;8(3):121–124.
   PubMedGoogle Scholar
• Gillis S, Hyam E, Abrahamov A, et al. Platelet function abnormalities in Gaucher disease patients. Am J Hematol. 1999 Jun;61(2):103–106.
   PubMed Web of Science ®Google Scholar
• Giona F, Palumbo G, Amendola A, et al. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT). J Thromb Haemost. 2006 Aug;4(8):1831–1833.
   PubMed Web of Science ®Google Scholar
• Spectre G, Roth B, Ronen G, et al. Platelet adhesion defect in type I Gaucher Disease is associated with a risk of mucosal bleeding. Br J Haematol. 2011 May;153(3):372–378.
   PubMed Web of Science ®Google Scholar
• Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013 Sep;39(6):621–631.
   PubMed Web of Science ®Google Scholar
• Komninaka V, Repa K, Marinakis T, et al. Platelet function defects in patients with Gaucher disease on long term ERT- implications for evaluation at bleeding challenges. Blood Cells Mol Dis. 2020 Feb;80:102371.
   PubMed Web of Science ®Google Scholar
• De Fost M, Out TA, De Wilde FA, et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol. 2008 Jun;87(6):439–449.
   PubMed Web of Science ®Google Scholar
• Rodic P, Pavlovic S, Kostic T, et al. Gammopathy and B lymphocyte clonality in patients with Gaucher type I disease. Blood Cells Mol Dis. 2013 Mar;50(3):222–225.
   PubMed Web of Science ®Google Scholar
• Rodic P, Lakocevic M, Pavlovic S, et al. Immunoglobulin heavy chain gene rearrangements in patients with Gaucher Disease. J Med Biochem. 2018 Jul;37(3):307–312.
   PubMed Web of Science ®Google Scholar
• Nair S, Branagan AR, Liu J, et al. Clonal immunoglobulin against lysolipids in the origin of myeloma. N Engl J Med. 2016 Feb 11;374(6):555–561.
   PubMed Web of Science ®Google Scholar
• Nguyen Y, Stirnemann J, Lautredoux F, et al. Immunoglobulin abnormalities in Gaucher Disease: an analysis of 278 patients included in the French Gaucher disease registry. Int J Mol Sci. 2020 Feb 13;21(4):1247.
   Web of Science ®Google Scholar
• Brautbar A, Elstein D, Pines G, et al. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis. 2004 Jan-Feb;32(1):214–217.
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Mistry PK, Rosenbloom BE, et al. MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association. Blood. 2018 May 31;131(22):2500–2501.
   PubMed Web of Science ®Google Scholar
• Monge J, Chadburn A, Gergis U. Synchronous multiple myeloma and Gaucher disease. Hematol Oncol Stem Cell Ther. 2020 Mar;13(1):42–45.
   PubMedGoogle Scholar
• Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005 Jun 15;105(12):4569–4572.
   PubMed Web of Science ®Google Scholar
• Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009 Apr;84(4):208–214.
   PubMed Web of Science ®Google Scholar
• Biegstraaten M, Cox TM, Belmatoug N, et al. Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis. 2018 Oct 24;68:203–208.
   PubMed Web of Science ®Google Scholar
• Hughes D, Cappellini MD, Berger M, et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol. 2007 Sep;138(6):676–686.
   PubMed Web of Science ®Google Scholar
• Zimran A, Ruchlemer R, Revel-Vilk S. A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):389–394.
   PubMedGoogle Scholar
• Arends M, Van Dussen L, Biegstraaten M, et al. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol. 2013 Jun;161(6):832–842.
   PubMed Web of Science ®Google Scholar
• Ruchlemer R, Amit-Kohn M, Tvito A, et al. Bone loss and hematological malignancies in adults: a pilot study. Support Care Cancer. 2018;26(9):9.
   Web of Science ®Google Scholar
• Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM. 1996 Sep;89(9):691–694.
   PubMed Web of Science ®Google Scholar
• Aflaki E, Westbroek W, Sidransky E. The complicated relationship between Gaucher Disease and Parkinsonism: insights from a rare disease. Neuron. 2017 Feb 22;93(4):737–746.
   PubMed Web of Science ®Google Scholar
• Revel-Vilk S, Szer J, Mehta A, et al. How we manage Gaucher Disease in the era of choices. Br J Haematol. 2018 Aug;182(4):467–480.
   PubMed Web of Science ®Google Scholar
• Dinur T, Zimran A, Becker-Cohen M, et al. Long term follow-up of 103 untreated adult patients with type 1 Gaucher Disease. J Clin Med. 2019 Oct 11;8(10):1662.
   PubMed Web of Science ®Google Scholar
• Kaluzna M, Trzeciak I, Ziemnicka K, et al. Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. Orphanet J Rare Dis. 2019 Dec 2;14(1):275.
   PubMed Web of Science ®Google Scholar
• Mistry PK, Balwani M, Baris HN, et al. Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells Mol Dis. 2018 Jul;71:71–74.
   PubMed Web of Science ®Google Scholar
• Giraldo P, Andrade-Campos M, Alfonso P, et al. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: the Spanish ZAGAL project. Blood Cells Mol Dis. 2018 Feb;68:173–179.
   PubMed Web of Science ®Google Scholar
• Balwani M, Burrow TA, Charrow J, et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016 Feb;117(2):95–103.
   PubMed Web of Science ®Google Scholar
• Belmatoug N, Di Rocco M, Fraga C, et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med. 2017 Jan;37:25–32.
   PubMed Web of Science ®Google Scholar
• Narita A, Shirai K, Itamura S, et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin Transl Neurol. 2016 3;Mar(3): 200–215.
   Google Scholar
• Istaiti M, Revel-Vilk S, Becker-Cohen M, et al. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: investigator initiated registry based on real life data. Am J Hematol. 2021. 10.1002/ajh.26131.
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Mengel E, Crawford N, et al. Venglustat in adult Gaucher disease type 3: preliminary safety, pharmacology, and exploratory efficacy from a phase 2 trial in combination with imiglucerase (LEAP). Mol Genet Metab. 2019;126(2):2.
   Web of Science ®Google Scholar
• Han TU, Sam R, Sidransky E. Small molecule chaperones for the treatment of Gaucher Disease and GBA1-Associated Parkinson Disease. Front Cell Dev Biol. 2020;8:271.
   PubMed Web of Science ®Google Scholar
• Dahl M, Smith EMK, Warsi S, et al. Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector. Mol Ther Methods Clin Dev. 2021 Mar 12;20:312–323.
   PubMed Web of Science ®Google Scholar
• Karponi G, Zogas N. Gene Therapy for beta-thalassemia: updated perspectives. Appl Clin Genet. 2019;12:167–180.
   PubMed Web of Science ®Google Scholar
• Arruda VR, Doshi BS, Arruda VR. Gene therapy for hemophilia: facts and quandaries in the 21st century. Mediterr J Hematol Infect Dis. 2020;12(1):e2020069.
   PubMedGoogle Scholar
• Revel-Vilk S, Chodick G, Shalev V, et al. Study design: development of an advanced machine learning algorithm for the early diagnosis of Gaucher Disease using real-world data. Blood. 2020;136(Supplement 1):13–14.
   Google Scholar
• Sanders KA, Gavrilov DK, Oglesbee D, et al. A comparative effectiveness study of newborn screening methods for four lysosomal storage disorders. Int J Neonatal Screen. 2020 Jun 6;6(2):44.
   PubMed Web of Science ®Google Scholar
• Hurvitz N, Dinur T, Becker-Cohen M, et al. Glucosylsphingosine (lyso-Gb1) as a biomarker for monitoring treated and untreated children with Gaucher Disease. Int J Mol Sci. 2019 Jun 21;20(12):12.
   Web of Science ®Google Scholar
• Cozma C, Cullufi P, Kramp G, et al. Treatment efficiency in Gaucher patients can reliably be monitored by quantification of Lyso-Gb1 concentrations in dried blood spots. Int J Mol Sci. 2020 Jun 27;21(13):4577.
   PubMed Web of Science ®Google Scholar
• Dinur T, Istaiti M, Frydman D, et al. Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease. Orphanet J Rare Dis. 2020 Oct 13;15(1):284.
   PubMed Web of Science ®Google Scholar
• Beutler E. Economic malpractice in the treatment of Gaucher’s disease. Am J Med. 1994 Jul;97(1):1–2.
   PubMed Web of Science ®Google Scholar
• Zimran A, Goldblatt J, Szer J. Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy. Blood Cells Mol Dis. 2018 Feb;68:14–16.
   PubMed Web of Science ®Google Scholar
• Cox TM, Mistry PK. Therapeutic position of eliglustat. Blood Cells Mol Dis. 2018 Mar;69:117–118.
   PubMed Web of Science ®Google Scholar
• Dasari SK, Schejter E, Bialik S, et al. Death by over-eating: the Gaucher disease associated gene GBA1, identified in a screen for mediators of autophagic cell death, is necessary for developmental cell death in Drosophila midgut. Cell Cycle. 2017;16(21):2003–2010.
   PubMed Web of Science ®Google Scholar
• Pandey MK, Grabowski GA, Kohl J. An unexpected player in Gaucher disease: the multiple roles of complement in disease development. Semin Immunol. 2018 Jun;37:30–42.
   PubMed Web of Science ®Google Scholar
• Barton NW, Furbish FS, Murray GJ, et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1913–1916.
   PubMed Web of Science ®Google Scholar
• Farfel-Becker T, Vitner EB, Futerman AH. Animal models for Gaucher disease research. Dis Model Mech. 2011 Nov;4(6):746–752.
   PubMed Web of Science ®Google Scholar